Fulltext

Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient

Robatel, C. ; Rusca, M. ; Padoin, C. ; Marchetti, O. ; Liaudet, L. ; Buclin, T.

In: Journal of Antimicrobial Chemotherapy, 2004, vol. 54, no. 1, p. 269-270

Ajouter à la liste personnelle
    Titre
    • Disposition of voriconazole during continuous veno-venous haemodiafiltration (CVVHDF) in a single patient
    Auteur
    • Robatel, C.. Division of Clinical Pharmacology and Toxicology
    • Rusca, M.. Division of Intensive Care Medicine
    • Padoin, C.. Pharmacy Department—CREPIT 93, Avicenne Hospital, Bobigny, France
    • Marchetti, O.. Infectious Diseases Service, Department of Medicine, University Hospital, 1011 Lausanne, Switzerland
    • Liaudet, L.. Division of Intensive Care Medicine
    • Buclin, T.. Division of Clinical Pharmacology and Toxicology
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Journal of Antimicrobial Chemotherapy, 2004, vol. 54, no. 1, p. 269-270. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:300278
    Summary
    Objectives: To determine whether voriconazole dosage adjustment is required during continuous veno-venous haemodiafiltration (CVVHDF). Methods: Voriconazole pharmacokinetics were studied in a critically ill patient under CVVHDF. The analysis was carried out for 12 h following a 6 mg/kg dose. Voriconazole concentrations were measured by HPLC in blood inlet and outlet lines and in dialysate. Results: The total body clearance of voriconazole was 20.3 L/h, with a terminal half-life of 13.7 h and a distribution volume of 399 L. The estimated sieving coefficient was 0.53 and the filtration-dialysis clearance 1.2 L/h. Conclusions: CVVHDF does not significantly affect voriconazole disposition and requires no dosage adjustment